Newsletter
Ensuring “Safety” Remains the Hallmark of Homeopathic OTCs
By Mark Land, M.S., RAC-US, AAHP President Monitoring and reporting on the safety of homeopathic drug products is a multifaceted undertaking that begins in the product development stage. Homeopathic drug…
Read MorePotential Nitrosamine Impurities in Your Products?
By Robert Sven Jechlitschka, Director of Quality and Development, Schwabe Pharma México In September 2024, the Food and Drug Administration published a final guidance document on Control of Nitrosamine Impurities…
Read MoreLowest Permissible Attenuation
By Eric L. Foxman, HPCUS Senior Scientist While many might be familiar with the nomenclature and concept of “First Safe Dilution” (FSD), the Homeopathic Pharmacopeia Convention of the United States…
Read MoreThe FDA Adverse Event Reporting System (FAERS)
By Kristina Skowronek, Dir. of Quality and Regulatory Compliance, Boiron, Inc. The FDA Adverse Event Reporting System (FAERS) has a public dashboard online where healthcare practitioners, retailers, consumers, and industry…
Read MoreUpdate — Lawsuit Challenges FDA’s Homeopathic Regulatory Policy
By Alvin J. Lorman, AAHP Counsel The lawsuit filed last October challenging FDA’s characterization of homeopathic products as unapproved new drugs will not be decided before the second quarter of…
Read MoreAAHP 2025 Outlook
By Mark Land, M.S., RAC-US, AAHP President To support the growth of member companies’ businesses and address issues in our new environment, the AAHP Board developed the following agenda built…
Read MoreA Year of Change
By Mark Land, M.S., RAC-US, AAHP President This year 2025 is poised to be one of the most dynamic years in recent memory. Everyone is aware by now of the…
Read MoreAAHP Reader Favorites for 2024
As we wrap up 2024, we’d like to take a moment to look back at our top articles from this year. These top five reads captured the attention of our…
Read MoreNew Rand Research Report: The State of Homeopathic Research
The Federal Trade Commission recently published rules regarding consumer endorsements and testimonials which take effect in less than two months. The rules are wide ranging and cover: relationships , compensation, prohibitions, misrepresentation or far more. Violators will be fined under the new rules. The AAHP has prepared a brief overview of …
Read More2024 Year in Review
By Mark Land, MS, RAC-US, AAHP President As 2024 comes to a close, let’s reflect on some of the news related to homeopathy and AAHP’s achievements. General News Affecting Homeopathy…
Read More